Comparison of the Revised 4th (2016) and 5th (2022) Editions of the World Health Organization Classification of Myelodysplastic Neoplasms

Overview

Journal Leukemia

Specialties Hematology
Oncology

Date 2022 Oct 12

PMID 36224330

Authors

Yudi Zhang

Junying Wu

Tiejun Qin

Zefeng Xu

Shiqiang Qu

Lijuan Pan

Bing Li

Huijun Wang

Peihong Zhang

Xin Yan

Jingye Gong

Qingyan Gao

Robert Peter Gale

Zhijian Xiao

Affiliations

Soon will be listed here.

Abstract

We used data from 852 consecutive subjects with myelodysplastic neoplasms (MDS) diagnosed according to the 2016 (revised 4th) World Health Organization (WHO) criteria to evaluate the 2022 (5th) edition WHO classification of MDS. 30 subjects previously classified as MDS with an NPM1 mutation were re-classified as acute myeloid leukaemia (AML). 9 subjects previously classified as MDS-U were re-classified to clonal cytopenia of undetermined significance (CCUS). The remaining 813 subjects were diagnosed as: MDS-5q (N = 11 [1%]), MDS-SF3B1 (N = 70 [9%]), MDS-biTP53 (N = 53 [7%]), MDS-LB (N = 293 [36%]), MDS-h (N = 80 [10%]), MDS-IB1 (N = 161 [20%]), MDS-IB2 (N = 103 [13%]) and MDS-f (N = 42 [5%]) and MDS-biTP53 (N = 53 [7%]). 34 of these subjects came from the 53 (64%) MDS-biTP53 previously diagnosed as MDS-EB. Median survival of subjects classified as MDS using the WHO 2022 criteria was 45 months (95% Confidence Interval [CI], 34, 56 months). Subjects re-classified as MDS-biTP53 and MDS-f had significantly briefer median survivals compared with other MDS sub-types (10 months, [8, 12 months] and 15 months [8, 23 months]). In conclusion, our analyses support the refinements made in the WHO 2022 proposal.

Citing Articles

The Impact of Microenvironment and Dysplasia Types on the Prognosis of Myelodysplastic Syndrome.

Bakkaloglu I, Zemheri I, Kaya A, Kilicaslan E Diagnostics (Basel). 2024; 14(23).

PMID: 39682628 PMC: 11639965. DOI: 10.3390/diagnostics14232720.

Decoy cells detected in the urine of a patient with complex karyotype Myelodysplastic neoplasms who underwent umbilical cord blood transplantation: a case report.

Zhou Y, Zhu S, Fang H, Zhou F, Jin J BMC Nephrol. 2024; 25(1):397.

PMID: 39501185 PMC: 11539637. DOI: 10.1186/s12882-024-03838-x.

Childhood and adolescent essential thrombocythemia and prefibrotic primary myelofibrosis: insights into diagnosis, outcomes, and treatment from a large Chinese cohort.

Fu R, Dong H, Gu W, Meng K, Sun T, Liu X Leukemia. 2024; 39(1):155-165.

PMID: 39375514 DOI: 10.1038/s41375-024-02432-2.

Identification of novel myelodysplastic syndromes prognostic subgroups by integration of inflammation, cell-type composition, and immune signatures in the bone marrow.

Gerlevik S, Seymen N, Hama S, Mumtaz W, Thompson I, Jalili S Elife. 2024; 13.

PMID: 39235452 PMC: 11377035. DOI: 10.7554/eLife.97096.

Impact of bone marrow fibrosis on outcomes of allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia.

Zhang H, Guo W, Wang J, Lu N, Zheng X, Sun Q Bone Marrow Transplant. 2024; 59(12):1654-1666.

PMID: 39192082 PMC: 11611735. DOI: 10.1038/s41409-024-02402-3.

References

Buesche G, Teoman H, Wilczak W, Ganser A, Hecker H, Wilkens L . Marrow fibrosis predicts early fatal marrow failure in patients with myelodysplastic syndromes. Leukemia. 2007; 22(2):313-22. DOI: 10.1038/sj.leu.2405030. View

Bennett J, Orazi A . Diagnostic criteria to distinguish hypocellular acute myeloid leukemia from hypocellular myelodysplastic syndromes and aplastic anemia: recommendations for a standardized approach. Haematologica. 2009; 94(2):264-8. PMC: 2635414. DOI: 10.3324/haematol.13755. View

Margolskee E, Hasserjian R, Hassane D, Tam W, Mathew S, Ok C . Myelodysplastic Syndrome, Unclassifiable (MDS-U) With 1% Blasts Is a Distinct Subgroup of MDS-U With a Poor Prognosis. Am J Clin Pathol. 2017; 148(1):49-57. DOI: 10.1093/ajcp/aqx043. View

Malcovati L, Stevenson K, Papaemmanuil E, Neuberg D, Bejar R, Boultwood J . SF3B1-mutant MDS as a distinct disease subtype: a proposal from the International Working Group for the Prognosis of MDS. Blood. 2020; 136(2):157-170. PMC: 7362582. DOI: 10.1182/blood.2020004850. View

Bono E, McLornan D, Travaglino E, Gandhi S, Galli A, Khan A . Clinical, histopathological and molecular characterization of hypoplastic myelodysplastic syndrome. Leukemia. 2019; 33(10):2495-2505. DOI: 10.1038/s41375-019-0457-1. View

Malcovati L, Karimi M, Papaemmanuil E, Ambaglio I, Jadersten M, Jansson M . SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring sideroblasts. Blood. 2015; 126(2):233-41. PMC: 4528082. DOI: 10.1182/blood-2015-03-633537. View

Fenaux P, Platzbecker U, Mufti G, Garcia-Manero G, Buckstein R, Santini V . Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes. N Engl J Med. 2020; 382(2):140-151. DOI: 10.1056/NEJMoa1908892. View

Valent P, Orazi A, Steensma D, Ebert B, Haase D, Malcovati L . Proposed minimal diagnostic criteria for myelodysplastic syndromes (MDS) and potential pre-MDS conditions. Oncotarget. 2017; 8(43):73483-73500. PMC: 5650276. DOI: 10.18632/oncotarget.19008. View

Huang H, Qin T, Xu Z, Shi Z, Li B, Pan L . Mutational features of myelodysplastic syndromes with Auer rods reveal them are more akin to acute myeloid leukemia. Br J Haematol. 2019; 188(5):796-800. PMC: 9204510. DOI: 10.1111/bjh.16326. View

10.

Della Porta M, Malcovati L, Boveri E, Travaglino E, Pietra D, Pascutto C . Clinical relevance of bone marrow fibrosis and CD34-positive cell clusters in primary myelodysplastic syndromes. J Clin Oncol. 2008; 27(5):754-62. DOI: 10.1200/JCO.2008.18.2246. View

11.

Feng G, Gale R, Cui W, Cai W, Huang G, Xu Z . A systematic classification of megakaryocytic dysplasia and its impact on prognosis for patients with myelodysplastic syndromes. Exp Hematol Oncol. 2016; 5:12. PMC: 4848808. DOI: 10.1186/s40164-016-0041-6. View

12.

Nazha A, Seastone D, Radivoyevitch T, Przychodzen B, Carraway H, Patel B . Genomic patterns associated with hypoplastic compared to hyperplastic myelodysplastic syndromes. Haematologica. 2015; 100(11):e434-7. PMC: 4825290. DOI: 10.3324/haematol.2015.130112. View

13.

Khoury J, Solary E, Abla O, Akkari Y, Alaggio R, Apperley J . The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms. Leukemia. 2022; 36(7):1703-1719. PMC: 9252913. DOI: 10.1038/s41375-022-01613-1. View

14.

Shiozawa Y, Malcovati L, Galli A, Sato-Otsubo A, Kataoka K, Sato Y . Aberrant splicing and defective mRNA production induced by somatic spliceosome mutations in myelodysplasia. Nat Commun. 2018; 9(1):3649. PMC: 6128865. DOI: 10.1038/s41467-018-06063-x. View

15.

Papaemmanuil E, Cazzola M, Boultwood J, Malcovati L, Vyas P, Bowen D . Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts. N Engl J Med. 2011; 365(15):1384-95. PMC: 3322589. DOI: 10.1056/NEJMoa1103283. View

16.

Montalban-Bravo G, Kanagal-Shamanna R, Sasaki K, Patel K, Ganan-Gomez I, Jabbour E . mutations define a specific subgroup of MDS and MDS/MPN patients with favorable outcomes with intensive chemotherapy. Blood Adv. 2019; 3(6):922-933. PMC: 6436014. DOI: 10.1182/bloodadvances.2018026989. View

17.

Fu B, Jaso J, Sargent R, Goswami M, Verstovsek S, Medeiros L . Bone marrow fibrosis in patients with primary myelodysplastic syndromes has prognostic value using current therapies and new risk stratification systems. Mod Pathol. 2013; 27(5):681-9. DOI: 10.1038/modpathol.2013.187. View

18.

Maassen A, Strupp C, Giagounidis A, Kuendgen A, Nachtkamp K, Hildebrandt B . Validation and proposals for a refinement of the WHO 2008 classification of myelodysplastic syndromes without excess of blasts. Leuk Res. 2012; 37(1):64-70. DOI: 10.1016/j.leukres.2012.09.021. View

19.

Matsuda A, Germing U, Jinnai I, Iwanaga M, Misumi M, Kuendgen A . Improvement of criteria for refractory cytopenia with multilineage dysplasia according to the WHO classification based on prognostic significance of morphological features in patients with refractory anemia according to the FAB classification. Leukemia. 2007; 21(4):678-86. DOI: 10.1038/sj.leu.2404571. View

20.

Bersanelli M, Travaglino E, Meggendorfer M, Matteuzzi T, Sala C, Mosca E . Classification and Personalized Prognostic Assessment on the Basis of Clinical and Genomic Features in Myelodysplastic Syndromes. J Clin Oncol. 2021; 39(11):1223-1233. PMC: 8078359. DOI: 10.1200/JCO.20.01659. View